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Objectives. We sought to determine the electrophysiologic
mechanisms explaining the efficacy of combination therapy with
DL-sotalol and a type Ia drug in the treatment of ventricular
tachycardia (VT).
Background. Combination antiarrhythmic drug therapy with
low dose DL-sotalol plus a type Ia antiarrhythmic agent has been
shown to prevent spontaneous and induced VT. The mechanisms
underlying the efficacy of this drug combination have not been
fully elucidated.
Methods. We studied 32 patients with spontaneous sustained
VT by using programmed electrical stimulation in the drug-free
condition and after treatment with DL-sotalol (average dose
[mean 6 SE] 151 6 8 mg/day) and a class Ia agent (quinidine,
1,337 6 59 mg/day, or procainamide, 2,083 6 327 mg/day).
Sustained VT was induced in all patients at baseline study, and
induction was reattempted during drug therapy. Monophasic
action potential duration at 90% repolarization (APD90) and
ventricular effective refractory period (ERP) were recorded with
use of a contact electrode.
Results. Ventricular ERP increased from 258 6 4 ms at
baseline to 310 6 6 ms at a 600-ms drive cycle length (DCL600)
with treatment (p < 0.001). APD90 increased from 288 6 6 ms by
110.1% at DCL600 and from 267 6 7 ms by 113.3% at a 400-ms
drive cycle length (DCL400) (p < 0.001). Paced QRS duration
increased from 141 6 3 to 158 6 6 ms at DCL400 (p < 0.05).
At baseline, the shortest achieved coupling interval between
successive propagated extrastimuli decreased progressively with
respect to the first extrastimulus, following double and triple
extrastimuli, at both DCL600 (214.0% and 220.0%, respectively)
and at DCL400 (216.4% and 222.4%, respectively). This “peeling
back” of refractoriness was attenuated on therapy with sotalol
plus a class Ia antiarrhythmic agent to 26.7% and 210.5%
(DCL600, p < 0.05), and 28.1%, 29.5% (DCL400, p < 0.05), for
double and triple extrastimuli, respectively. The absolute prolon-
gation of functional refractory periods by the drug combination
increased with successive extrastimuli, from 55 6 6 ms for the
V1V2 interval to 75 6 6 ms for V2V3 and 67 6 6 ms for V3V4 at
DCL600, and from 51 6 5 ms for V1V2 to 69 6 6 ms for V2V3 and
74 6 7 ms for V3V4 at DCL400 (p < 0.001).
Conclusions. The combination of low dose sotalol and a class Ia
agent greatly prolongs refractoriness. The magnitude of the effect
increases at shorter coupling intervals.
(J Am Coll Cardiol 1997;29:100–5)
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Electropharmacologic studies of ventricular tachycardia have
demonstrated the importance of lengthening of repolarization
and prolongation of refractoriness in predicting a favorable
response to drug therapy (1,2). Drugs that prolong cardiac
refractoriness such as sotalol or amiodarone appear to be
superior to sodium channel blocking agents, which primarily
slow cardiac conduction, in preventing recurrent ventricular
tachycardia (VT) or sudden death (3,4). However, prolonga-
tion of action potential duration (class III effect) is often
characterized by a progressive loss of effect at higher stimula-
tion rates, otherwise known as “reverse use dependence” (5).
A drug or combination of drugs that prolong ventricular
refractoriness, and whose effects are preserved at high cardiac
frequencies, would be expected to be clinically useful in
preventing induced and spontaneous VT (5). Amiodarone may
have some of these properties (6), which may be the result of
combined sodium channel blocking and action potential pro-
longation (5). Combination antiarrhythmic therapy with low
dose DL-sotalol and a type Ia antiarrhythmic agent is highly
effective in preventing or modifying inducible VT at electro-
physiologic study and in preventing recurrences of spontane-
ous VT (7). The aim of the present study was to elucidate the
electrophysiologic mechanisms underlying the efficacy of this
drug combination.
We hypothesized that moderate doses of these antiarrhyth-
mic agents would minimize the incidence of adverse effects
while maintaining a beneficial effect on ventricular refractori-
ness. Furthermore, we postulated that the drug combination
would attenuate the reverse use dependent effect on refracto-
riness after successive extrastimuli expected with “pure” class
III activity. This study examines the effect of DL-sotalol and
quinidine or procainamide on simultaneous measures of ven-
tricular refractoriness and monophasic action potential (MAP)
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duration in response to extrastimuli in patients undergoing
electrophysiologic study.
Methods
Study patients. Patients were referred to the cardiac elec-
trophysiology service for evaluation and treatment of docu-
mented or suspected sustained VT or ventricular fibrillation
(VF). Thirty-two patients underwent baseline electrophysi-
ologic study in the absence of antiarrhythmic medications
(discontinuation of all antiarrhythmic drugs for $5 half-lives)
and were found to have inducible sustained monomorphic VT
at baseline study. No patient had received amiodarone in the
previous 6 months. All patients had been treated with at least
one antiarrhythmic drug that failed to suppress inducible
sustained VT.
Electrophysiologic testing. Programmed electrical stimula-
tion was performed with the patient in the fasting sedated state
with use of a constant current stimulator (Medtronic Inc.)
applying rectangular pulses of 2-ms duration at twice diastolic
threshold. Induction of VT was attempted with single, double
and triple ventricular extrastimuli delivered to the right ven-
tricular apex and decrementing in 10-ms steps to ventricular
refractoriness or 200 ms. Coupling intervals were not decre-
mented beyond 200 ms to avoid inducing polymorphic VT or
VF. Further extrastimulation was not attempted if VT or VF
was induced with single or double extrastimuli. Decremental
extrastimuli were delivered after eight-beat trains of ventricu-
lar pacing with 3-s intertrain pauses.
The ventricular effective refractory period (ERP) was mea-
sured by the decremental extrastimulus technique at cycle
lengths of 600 and 400 ms (DCL600 and DCL400, respectively)
in the drug-free condition and during treatment with S 1 Ia.
The ventricular ERP was the longest S1S2 interval at which S2
failed to capture. Monophasic action potentials were measured
by a quadripolar contact monophasic action potential record-
ing electrode (EPT Technologies Inc.), allowing for recording
of action potential signals that are determined from the same
population of myocardial cells for which refractory period
measurements were made (8,9). Action potential duration
(APD) at 90% repolarization (APD90) was measured as pre-
viously reported (9). To determine the shortest coupling
intervals for triple extrastimulation, stimulus to stimulus inter-
vals were decremented in 10-ms steps for the first, second and
third extrastimuli until noncapture resulted for each. The
shortest coupling intervals for each of S2, S3, and S4 achieving
ventricular capture were designated the “shortest coupling
interval.”
Combination drug therapy. Sotalol and either quinidine or
procainamide were administered orally, and repeat electro-
physiologic study was conducted $72 h after the initiation of
combination drug therapy. Patients were treated with 80 or
160 mg of sotalol twice daily with the dose adjusted downward
if dose-related adverse effects appeared before repeat electro-
physiologic study. Quinidine (as quinidine bisulfate) was ad-
ministered in doses of 500 mg two or three times daily.
Procainamide (slow release formulation) was given as 500 to
1,500 mg every 6 h.
Definitions. We used the following definitions: Spontane-
ous or induced sustained VT was monoform VT lasting .30 s
or causing syncope or hemodynamic deterioration requiring
immediate termination of the arrhythmia. Inducible VT was
$15 repetitive ventricular responses after programmed stimu-
lation. Modified VT inducibility was induced VT meeting all of
the following prospectively defined criteria as previously de-
fined (7): 1) induced VT cycle length $50 ms longer than the
baseline induced VT cycle length; 2) pacing termination of
induced VT was possible; and 3) the induced VT was well
tolerated with mild or no symptoms and no presyncope or loss
of consciousness. Although intraarterial blood pressure was
measured for all patients, no specific blood pressure cutoff
point was included in the definition. Patients whose VT was
rendered noninducible (#15 repetitive ventricular responses)
by the combination drug therapy or whose inducible VT was
modified were eligible for long-term treatment on this regi-
men. Patients whose arrhythmia did not meet either of these
criteria (unmodified VT) were treated with other regimens.
S1, S2, S3 and S4 represent stimulus artifacts of the last beat
of the ventricular drive train and of the first, second and third
extrastimulus, respectively. Corresponding ventricular electro-
grams resulting from these stimuli are designated V1, V2, V3
and V4. Ventricular functional refractory period (FRP) was
measured as the shortest interval from onset of the upstroke of
the MAP to onset of the immediately following MAP upstroke,
where both stimuli in the sequence resulted in ventricular
depolarization. Shortest intervals between successive MAP
upstrokes for S1S2, S2S3 and S3S4 are designated as FRP, FRP3
and FRP4, respectively. The QRS duration of the last complex
of the eight-beat ventricular drive train at cycle lengths of 600
and 400 ms was measured from surface lead V1 at 100-mm/s
paper speed and was used as a measure of ventricular conduc-
tion.
Statistical analysis. Continuous variables were compared
using the Student t test or two-way analysis of variance for
repeated measures where appropriate; p values , 0.05 were
considered significant. The Duncan multiple range test was
used for multiple comparisons. All data are expressed as mean
value 6 SE unless otherwise indicated.
Abbreviations and Acronyms
APD 5 action potential duration
APD90 5 action potential duration at 90% repolarization
DCL400 5 drive cycle length at 400 ms
DCL600 5 drive cycle length at 600 ms
ERP 5 effective refractory period
FRP 5 functional refractory period
MAP 5 monophasic action potential
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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Results
Study patients. There were 28 men and 4 women with a
mean age 6 SD of 63 6 11 years. Most patients (97%) had
coronary artery disease, and one patient had idiopathic VT,
with a mean 6 SD ejection fraction of 29 6 11%. The largest
group of patients (47%) presented with sustained VT without
syncope; the others had VF (25%) or sustained VT with
syncope (28%). All patients had inducible sustained VT at
baseline study. There were no documented instances of tor-
sade de pointes in the study group over $2 years of follow-up.
Of the 32 patients, 26 were studied while taking sotalol plus
quinidine and 6 while taking sotalol plus procainamide. The
average drug dosages were as follows: sotalol, 151 6 8 mg/day;
quinidine, 1,337 6 59 mg/day; and procainamide 2,083 6
327 mg/day.
Ventricular ERP. Baseline ventricular ERP was 258 6
4 ms and increased significantly to 310 6 6 ms (120.2%)
during therapy at DCL600 (p , 0.001). At DCL400, ventric-
ular ERP also increased significantly from 242 6 4 to 292 6
5 ms (120.7%) (p , 0.001). With successive extrastimulus
delivery, there was a significant progressive decline in the
shortest coupling intervals (i.e., S3S4 vs. S2S3; S2S3 vs. S1S2)
(p , 0.01, p , 0.05 for DCL400 and DCL600, respectively)
(Table 1). The study was discontinued without progressing
further to double or triple extrastimuli if sustained VT was
induced with single or double extrastimuli, respectively. Thus,
fewer patients received triple extrastimuli: nine patients at
DCL600 (control) and eight patients at DCL400. With ther-
apy, it became more difficult to induce VT, and more patients
received triple extrastimuli: 17 patients at DCL600 and 14
patients at DCL400.
Ventricular FRP. Ventricular FRP during treatment with
sotalol plus a type Ia antiarrhythmic agent was significantly
prolonged at both DCL600 and DCL400, from 291 6 3 ms
(control) to 334 6 6 ms at DCL600 (114.9% vs. control, p ,
0.001) and from 2736 3 ms (control) to 3156 4 ms at DCL400
(115.7% vs. control, p , 0.001) (Fig. 1). There was a signifi-
cant progressive decline in shortest MAP upstroke to subse-
quent MAP upstroke interval with successive extrastimuli (i.e.,
FRP4 ,FRP3 ,ventricular FRP) in the control state (repre-
senting “peeling back” of refractoriness) at both DCL600 and
DCL400 (p , 0.0001). Compared with the shortest V1V2
interval during single extrastimulus delivery (i.e., ventricular
FRP), the shortest V2V3 interval (FRP3) and shortest V3V4
interval (FRP4) in the control state decreased by 214.0% and
220.0%, respectively, at DCL600. Similarly, at DCL400, the
shortest MAP to MAP interval decreased with successive
extrastimuli by 216.4% (FRP3) and 222.4% (FRP4) (Fig. 1).
During drug therapy with sotalol and a type Ia agent, this
shortening of refractoriness was attenuated significantly (p ,
0.0001 for drug effect). The percent decline relative to ventric-
ular FRP was significantly reduced for the shortest V2V3
interval (or FRP3) and the shortest V3V4 interval (or FRP4) at
both DCL600 and DCL400 (p , 0.01). There was a significant
drug by number of extrastimuli interaction (p , 0.002); that is,
the slope of FRP versus the number of extrastimuli was
significantly less steep after drug therapy than at baseline (Fig.
1). FRP3 and FRP4 shortened only by 26.6% (334 6 6 to
312 6 9) and 210.5% (334 6 6 to 299 6 8), respectively, at
DCL600 and by 28.0% (315 6 4 to 290 6 6) and 29.5%
(315 6 4 to 285 6 8) respectively at DCL400.
The absolute prolongation of refractoriness with respect to
baseline control, representing drug effect, increased with suc-
cessive extrastimuli (Fig. 2). Increasing number of extrastimuli
resulted in more absolute prolongation of FRP, with an
increase in drug effect from 55 6 6 ms at V1V2, to 75 6 6 ms
at V2V3 (p , 0.001 vs. V1V2) and to 67 6 6 ms at V3V4 (p ,
0.001 vs. V1V2), respectively, at DCL600. At DCL400, the
corresponding values were 51 6 5 ms (V1V2), 69 6 6 ms
(V2V3; p , 0.001 vs. V1V2) and 74 6 7 ms (V3V4; p , 0.001
vs. V1V2).
APD and ERP/APD90 ratio. APD90 prolonged significantly
during therapy with sotalol and a type Ia agent as compared
with control values at both cycle lengths. APD90 increased
from 288 6 6 to 318 6 4 ms at DCL600 ms (110.1% vs.
Figure 1. Ventricular functional refractory period (VFRP) (V1 up-
stroke to V2 upstroke) and shortest intervals for the V2 to V3 upstroke
(FRP3) and V3 to V4 upstroke (FRP4) on no antiarrhythmic drug
regimen at cycle lengths of 400 ms (control 400) and 600 ms (control
600); and during therapy with sotalol and a class Ia agent at cycle
lengths of 400 ms (S1 IA 400) and 600 ms (S1 IA 600). In the control
group, progressive shortening of FRP with repetitive extrastimuli is
seen and is attenuated with therapy. This figure includes all patients
who received single, double or triple extrastimuli.
Table 1. Shortest Coupling Intervals
DCL
(ms)
S1S2
(ms)
S2S3
(ms)
S3S4
(ms)
600
Control 2836 6
*
239 6 9
*
234 6 10
*
S 1 IA 334 6 8 ] 324 6 8 ] 305 6 8 ]
400
Control 253 6 9
*
225 6 8
*
216 6 7
*
S 1 IA 308 6 5 ] 296 6 7 ] 283 6 8 ]
*p , 0.001 versus control. Shortest coupling (stimulus to stimulus) intervals
with triple extrastimuli in control without therapy and in patients receiving
therapy with low dose sotalol plus a type Ia (S 1 IA) agent (quinidine or
procainamide). Only patients with triple extrastimuli are included in this analysis.
DCL 5 drive cycle lengths.
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control, p , 0.001). At DCL400, APD90 increased from 267 6
7 to 303 6 5 ms (113.3% vs. control, p , 0.001). Control
APD90 decreased by 27.5% from DCL600 to DCL400. The
drug combination attenuated this decrease in APD90 to24.8%
(p , 0.05).
The ERP/APD90 ratio in the control state at DCL600 was
0.89 6 0.01. This increased to 0.98 6 0.02 during therapy with
sotalol plus a type Ia agent at DCL600 (p , 0.05). The
ERP/APD90 ratio at DCL400 also increased, from 0.91 6 0.01
to 0.97 6 0.01 (p , 0.05). The VERP/APD ratios for patients
receiving therapy did not change with repetitive extrastimuli.
Thus, with the combination therapy, ERP/APD ratios for S2S3
and S3S4 were 0.90 6 0.02 and 0.90 6 0.02 (at DCL600) and
0.98 6 0.03 and 0.98 6 0.03 (at DCL400), respectively.
ERP/APD ratios for control patients were not analyzed be-
cause of the small numbers of patient studies available for
comparison.
QRS duration. QRS duration at DCL600 at baseline was
1346 5 ms. There was no significant increase in QRS duration
at DCL400, which was 141 6 3 ms (p 5 NS vs. DCL600).
During therapy with sotalol and either procainamide or quin-
idine, there was a slight conduction delay: QRS duration
increased from 1346 5 to 1516 5 ms at DCL600, representing
an increase of 112.7% (p , 0.05). At DCL400, QRS duration
increased by 111.9%, from 141 6 3 to 158 6 6 ms (p , 0.05).
Clinical outcome. Among 32 patients who underwent a
trial of sotalol plus a type Ia agent, VT was rendered nonin-
ducible in 15 and was modified in 12; these 27 patients were
discharged receiving sotalol plus a type Ia agent. The remain-
ing five patients received other drug therapy. Fourteen of the
27 patients continued to receive the drug without interruption
throughout the follow-up period (2 years). The other 13
discontinued therapy because of side effects (9 patients) or
recurrence of arrhythmia (4 patients) and underwent other
treatment: implantable cardioverter-defibrillator implantation
(6 patients), VT surgery (1 patient) or another drug regimen (6
patients). One patient, with recurrent arrhythmia, was resus-
citated from cardiac arrest during therapy with sotalol and
quinidine; he underwent VT surgery and subsequently died
suddenly while being treated with amiodarone.
Discussion
The main findings of this study are that combination
therapy with DL-sotalol and a type Ia drug prolongs the ERP
and APD and that the magnitude of this effect increases with
repetitive extrastimulation. The ERP/APD ratio was pro-
longed and unaffected by repetitive extrastimuli. We (7) have
previously shown that this drug combination prevents recur-
rence of arrhythmia in patients with modified or noninducible
tachycardia and thus has clinical benefit.
Prolongation of ventricular refractoriness is beneficial in
suppression of VT, with an increase in right ventricular ERP
being correlated with antiarrhythmic efficacy (10). Multicenter
randomized trials (3,11) have shown sotalol to be more effec-
tive than type I agents alone in suppressing VT and this may be
a result of refractoriness prolongation without conduction
delay. Furukawa et al. (12) demonstrated that more prolonga-
tion of refractoriness and relatively less slowing of intraven-
tricular conduction was useful in preventing VT. Subsequent
studies (13,14) have confirmed that ventricular ERP prolonga-
tion with either quinidine or procainamide is a predictor of
drug efficacy. Our study confirms in vitro findings (15) that the
drug combination results in additive prolongation of repolar-
ization and refractoriness with minimal slowing of conduction.
Prolongation of refractoriness results from prolongation of
the APD and postrepolarization refractoriness. Sotalol in-
creases refractoriness without affecting conduction (16). Low
doses (160 to 320 mg/day) of sotalol prolong repolarization
(17), but the effect of sotalol alone on ERP at the doses used
in this study is modest (18). The beta-blocking actions of
DL-sotalol probably contribute to its clinical efficacy because
D-sotalol, which is devoid of beta-blocking action, increases
mortality in patients with left ventricular dysfunction after
myocardial infarction (19).
Agents with class Ia action also prolong refractoriness, in
part by a direct effect on prolongation of APD by the parent
drug or its metabolites and in part by causing postrepolariza-
tion refractoriness. Quinidine and procainamide exhibit a class
III effect by inhibiting Ik (delayed outward rectifier potassium
current) in a time- and voltage-dependent manner thus pro-
longing APD (20,21). Quinidine also blocks multiple potas-
sium currents other than Ik in vitro, including Ito and Ik1 (22).
These class III effects are more marked at long cycle lengths
whereas sodium channel blockade (depression of maximal rate
of increase of action potential upstroke [Vmax]) occurs to a
greater degree at shorter cycle lengths (23,24). Furthermore,
class Ia drugs cause postrepolarization refractoriness by a
relatively greater increase in refractoriness relative to repolar-
ization (24). Drug combinations of class I agents with beta-
blockers prolong refractoriness to a greater degree than would
be expected from the class I agent alone (25), and this may be
due to adrenergic effects on potassium currents (26). Adren-
ergic stimulation can shorten the APD by increasing the
magnitude of Ik currents (26) and thus attenuate the effect of
class III drugs (27). Newman et al. (28) found that drug-
mediated APD and refractoriness prolongation are attenuated
by isoproterenol, independently of rate (28). Thus, refractori-
ness prolongation by both lengthening APD and postrepolar-
ization refractoriness, which has been demonstrated with the
drugs on an individual basis, can be augmented when the drugs
are used in combination.
Reverse use dependence. A potentially important finding is
the effect on “reverse use dependence.” Certain “pure” class
III agents, such as sotalol, exhibit less relative APD or ERP
prolongation as cycle length decreases, with almost complete
loss of effect at short cycle lengths (29,30). The term “reverse
use dependence” has been proposed by Hondeghem and
Snyders (5) to represent this effect, implying that there is less
antiarrhythmic effectiveness at shorter cycle lengths. It has
been speculated that some of this rate-related shortening of
APD and loss of drug-related APD prolongation may be due to
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a relatively greater contribution of Iks, a slowly activating
outward potassium current (31), at faster rates. We hypothe-
sized that the combination of class I and class III agents and
beta-blockade may eliminate reverse use dependence. If one
defines drug effect as the relative difference in electrophysi-
ologic measures from control values, the relatively greater
effect on refractory periods for subsequent extrastimuli versus
the first extrastimulus represents positive rate dependence of
drug effect. This effect occurs on the background of shortening
of APD and refractoriness normally seen with successive
extrastimuli, accounting for the overall shorter FRP for the
third versus the second and first extrastimulus. The absolute
difference in FRP between treated and untreated groups is
greater for the third versus the first extrastimulus, suggesting
that there is greater drug effect at faster rates (Fig. 2).
ERP/APD relation. Koller et al. (32) demonstrated the
“peeling back” of functional refractoriness with successive
extrastimuli in the control state. Repetitive extrastimulation
shortened both APD and the ERP/APD ratio, and capture
occurred at progressively less complete repolarization levels
resulting in a higher incidence of VT induction (32). This
progressive encroachment of the preceding repolarization
phase is eliminated by sotalol plus a type Ia agent, resulting in
an increased and unchanging ERP/APD ratio with repetitive
extrastimulus delivery. Our results support the hypothesis that
the changing ERP/APD relation with repetitive, closely cou-
pled extrastimuli is conducive to VT induction (32). Procain-
amide has been shown to exhibit a cycle length–dependent
increase in ERP relative to APD, which may reflect use-
dependent sodium channel blockade (24), and thus the addi-
tion of a class Ia agent may be responsible for the postrepo-
larization refractoriness which is evident even at close coupling
intervals and at faster drive rates. However, this cycle length–
dependent increase of ERP for type Ia drugs alone occurs at
the cost of increasing conduction slowing and is more modest
than the marked ERP and FRP increases seen with the
sotalol-type Ia combination.
In our baseline studies, we stopped continued extrastimu-
lation at a coupling interval of 200 ms (S3S4), even if VT was
not induced, and thus we may have overestimated the FRP,
particularly at V3V4 (FRP4). During treatment with sotalol and
a type Ia drug, no patient had an FRP ,230 ms. The net result
was that the true increase in V3V4 (FRP4) may be even greater
than we have observed, and the divergence between treatment
and control groups shown in Figure 1 may be larger than
illustrated.
Despite marked prolongation of refractoriness, no patient
had documented torsade de pointes. Refractoriness was in-
creased markedly with a moderate increase in APD, probably
secondary to the relatively low drug doses employed. There
was a minimal but significant increase in ventricular conduc-
tion slowing with sotalol plus a type Ia agent. Thus, the
combined effects of these two drugs had a positive effect on
increasing refractoriness and in maintaining this effect at faster
rates while potentially minimizing the potentially harmful
electrophysiologic effects of high drug dosages, including tor-
sade de pointes and markedly prolonged conduction delay.
Study limitations. Electrophysiologic studies were discon-
tinued when sustained VT was induced; thus, some patients
did not undergo testing with double or triple extrastimuli at
faster rates. Data on FRP4 intervals may therefore be available
only for the subgroups whose arrhythmia was difficult to induce
or noninducible, and they may represent a subset of the
patients with greater drug effect. However, higher drug dose or
concentration was not responsible for the observed clinical
efficacy or longer ERP in these subgroups (7).
Patients in this study had simultaneous recordings of MAPs
and surface electrocardiograms (ECGs), although eight had
only ECG recordings. In these cases, RR intervals were used in
FRP analysis since the effect of the drug combination on
conduction was small, the difference in the local MAP to
surface QRS onset interval was likely to be very small.
Use dependence of drug action is usually assessed at steady
state pacing, after $60 s. We assessed rate (use) dependence
after successive extrastimuli, or “step” increases in rate. How-
ever, much of rate-related APD shortening is evident after the
first few beats at a faster rate (33), and all comparisons are
made with respect to the same methods before and after drug
therapy. In addition, an 8-beat drive train might not have been
long enough to attain a steady state of effect on refractoriness,
but steady state is almost achieved (33) and is clinically
relevant for VT induction. Finally, we were not able to study
patients given monotherapy with sotalol or a class Ia drug, but
the ERP prolongation in this study is greater than has been
seen with either drug as monotherapy and probably reflects the
combined effect of both drugs.
We thank Kim Brown for secretarial assistance in the preparation of the
manuscript and Jan Mitchell, RN for technical assistance.
Figure 2. Absolute increase (in ms) in FRP after delivery of single
(V1V2), double (V2V3) and triple (V3V4) extrastimuli in patients
receiving sotalol plus a type I antiarrhythmic agent versus control at
drive cycle lengths of 600 (DCL600) and 400 (DCL400) ms. There is
greater prolongation of FRP for successive beats as the coupling
interval shortens, implying greater drug effect at faster rates (positive
use-dependent effect).
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